Passive immunotherapy prevents expression of endogenous Moloney virus and amplification of proviral DNA in BALB/Mo mice.
BALB/Mo mice carrying the Moloney murine leukemia virus (M-MuLV) as an endogenous virus become viremic soon after birth and develop leukemia at a later age. M-MuLV-specific gene expression and an increase of virus-specific DNA copies in lymphatic target organs are characteristics of the preleukemic phase. Passive immunotherapy of new born BALB/Mo mice with anti-gp70 glycoprotein or anti-M-MuLV serum prevented viremia and delayed significantly the subsequent development of leukemia. Molecular hybridization experiments showed that both virus-specific genome transcription and virus-specific DNA amplification could be completely suppressed by antiserum treatment. Thus virus-specific RNA concentrations in target organs of immunized BALB/Mo mice of 6 months or older were as low as in normal BALB/c mice. This is an age at which untreated BALB/Mo mice have already developed malignant lymphoma. Our experiments demonstrate that treatment with antiserum interferes with the early events of virus expression and thus prevents the subsequent steps leading to leukemia.[1]References
- Passive immunotherapy prevents expression of endogenous Moloney virus and amplification of proviral DNA in BALB/Mo mice. Nobis, P., Jaenisch, R. Proc. Natl. Acad. Sci. U.S.A. (1980) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg